Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Mahfoud

Showing results (271-280 of 614) with videos related to

Pageof 62
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 10, 2021
Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 yearsChristian Ott, Felix Mahfoud, Giuseppe Mancia, et al.
Hypertension (Dallas, Tex. : 1979)|April 4, 2024
Impact of Renal Denervation on Urinary Peptide-Based Biomarkers in HypertensionLucas Lauder, Justyna Siwy, Emmanouil Mavrogeorgis, et al.
International Journal of Cardiology|April 1, 2014
Improvement of albuminuria after renal denervationChristian Ott, Felix Mahfoud, Axel Schmid, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 5, 2018
Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medicationsLucas Lauder, Sebastian Ewen, Michel Azizi, et al.
Trials|December 22, 2015
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registryPeter Bramlage, Roland E Schmieder, Anselm K Gitt, et al.
Contemporary Clinical Trials Communications|July 14, 2021
A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptionsMichael Böhm, Martin Fahy, Graeme L Hickey, et al.
Frontiers in Neurology|May 16, 2022
Ischemic Stroke-A Scientometric AnalysisDominic Millenaar, Andreas Ragoschke-Schumm, Tobias Fehlmann, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
PEERLESS II: A Randomized Controlled Trial of Large-Bore Thrombectomy Versus Anticoagulation in Intermediate-Risk Pulmonary EmbolismJay Giri, Felix Mahfoud, Bernhard Gebauer, et al.
JACC. Cardiovascular Imaging|June 26, 2026
Expert Human Readers vs ECG Criteria for Detecting Left Ventricular Hypertrophy: A CMR-Based ComparisonJedrzej Sarnecki, Ramun Schmid, Patrick Badertscher, et al.
BMC Cardiovascular Disorders|July 4, 2013
EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registryAnselm K Gitt, Peter Baumgart, Peter Bramlage, et al.
Pageof 62

Showing results (271-280 of 614) with videos related to

Sort By:
Pageof 62
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 10, 2021
Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 yearsChristian Ott, Felix Mahfoud, Giuseppe Mancia, et al.
Hypertension (Dallas, Tex. : 1979)|April 4, 2024
Impact of Renal Denervation on Urinary Peptide-Based Biomarkers in HypertensionLucas Lauder, Justyna Siwy, Emmanouil Mavrogeorgis, et al.
International Journal of Cardiology|April 1, 2014
Improvement of albuminuria after renal denervationChristian Ott, Felix Mahfoud, Axel Schmid, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 5, 2018
Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medicationsLucas Lauder, Sebastian Ewen, Michel Azizi, et al.
Trials|December 22, 2015
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registryPeter Bramlage, Roland E Schmieder, Anselm K Gitt, et al.
Contemporary Clinical Trials Communications|July 14, 2021
A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptionsMichael Böhm, Martin Fahy, Graeme L Hickey, et al.
Frontiers in Neurology|May 16, 2022
Ischemic Stroke-A Scientometric AnalysisDominic Millenaar, Andreas Ragoschke-Schumm, Tobias Fehlmann, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
PEERLESS II: A Randomized Controlled Trial of Large-Bore Thrombectomy Versus Anticoagulation in Intermediate-Risk Pulmonary EmbolismJay Giri, Felix Mahfoud, Bernhard Gebauer, et al.
JACC. Cardiovascular Imaging|June 26, 2026
Expert Human Readers vs ECG Criteria for Detecting Left Ventricular Hypertrophy: A CMR-Based ComparisonJedrzej Sarnecki, Ramun Schmid, Patrick Badertscher, et al.
BMC Cardiovascular Disorders|July 4, 2013
EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registryAnselm K Gitt, Peter Baumgart, Peter Bramlage, et al.
Pageof 62